文献速递泌尿生殖骨肌PETCT

68Ga-PSMA-11 PET/CT与99mTc-MDP骨显像检测前列腺癌骨转移的头对头比较:一项Meta分析

Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis.
PubMed 文献 · AJR Am J Roentgenol · 2022-04-20

该Meta分析纳入6项研究共546例前列腺癌患者,头对头比较68Ga-PSMA-11 PET/CT与99mTc-MDP骨显像检测骨转移的诊断性能。68Ga-PSMA-11 PET/CT的汇总敏感度和特异度分别为98%和97%,优于99mTc-MDP骨显像的83%和68%;AUC分别为0.99和0.85。在99mTc-MDP骨显像阴性的193例患者中,68Ga-PSMA-11 PET/CT正确识别出43例(22.3%)骨转移。

要点

  • 68Ga-PSMA-11 PET/CT检测前列腺癌骨转移的汇总敏感度98%、特异度97%,AUC 0.99。
  • 99mTc-MDP骨显像汇总敏感度83%、特异度68%,AUC 0.85,均低于68Ga-PSMA-11 PET/CT。
  • 99mTc-MDP骨显像阴性者中68Ga-PSMA-11 PET/CT额外检出22.3%骨转移,反之仅1.9%。

核心结论

  • 基于患者水平的分析显示,68Ga-PSMA-11 PET/CT检测前列腺癌骨转移的诊断性能优于99mTc-MDP骨显像,且99mTc-MDP骨显像在68Ga-PSMA-11 PET/CT阴性患者中提供的额外信息有限。

研究设计与样本

  • Meta分析,检索PubMed、Embase和Cochrane Library数据库至2021年10月,纳入6项头对头比较研究共546例前列腺癌患者,仅纳入参考标准明确(影像学和/或临床随访的各种组合)的研究,采用双变量随机效应模型计算汇总诊断性能,并通过分层汇总ROC分析得出各检查的AUC。

诊断标准与关键数值

  • 68Ga-PSMA-11 PET/CT汇总敏感度98%(95%CI 94-99%)、特异度97%(95%CI 91-99%)、AUC 0.99(95%CI 0.96-1.00);99mTc-MDP骨显像汇总敏感度83%(95%CI 69-91%)、特异度68%(95%CI 41-87%)、AUC 0.85(95%CI 0.81-0.87)。

临床应用与阅片要点

  • 在68Ga-PSMA-11 PET/CT结果为阴性的患者中,99mTc-MDP骨显像正确识别出4/210例(1.9%)骨转移;在99mTc-MDP骨显像阴性的患者中,68Ga-PSMA-11 PET/CT正确识别出43/193例(22.3%)骨转移。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Bone scintigraphy (BS) using 99mTc-labeled methylene diphospho-nate (99mTc-MDP) remains the recommended imaging modality for the detection of bone metastases in patients with prostate cancer (PCa). However, PET/CT using prostate-specific membrane antigen (PSMA) ligands is increasingly recognized as a means of evaluating disease extent in patients with PCa, including use as a possible stand-alone test in high-risk patients. OBJECTIVE. The purpose of this study is to compare the diagnostic performance of 68Ga-PSMA-11 PET/CT with that of 99mTc-MDP BS for the detection of bone metastases in patients with PCa. EVIDENCE ACQUISITION. The PubMed, Embase, and Cochrane Library databases were searched through October 2021 to identify studies reporting a head-to-head comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP BS for the detection of bone metastases in patients with PCa. Only studies with a well-defined reference standard (including various combinations of imaging and/or clinical follow-up) were included. Pooled diagnostic performance was calculated using a bivariate random-effects model, and an AUC was derived for each test from hierarchic summary ROC analysis. The complementary roles of the two tests in identifying bone metastases in patients in whom one of the tests was negative were summarized. EVIDENCE SYNTHESIS. Six studies with 546 patients were included. Pooled sensitivity and specificity, respectively, were 98% (95% CI, 94-99%) and 97% (95% CI, 91-99%) for 68Ga-PSMA-11 PET/CT versus 83% (95% CI, 69-91%) and 68% (95% CI, 41-87%) for 99mTc-MDP BS. The AUC was 0.99 (95% CI, 0.96-1.00) for 68Ga-PSMA-11 PET/CT and 0.85 (95% CI, 0.81-0.87) for 99mTc-MDP BS. Among 408 patients from five included studies, 68Ga-PSMA-11 PET/CT correctly identified bone metastases in 43 of 193 patients (22.3%) with negative 99mTc-MDP BS results, whereas 99mTc-MDP BS correctly identified bone metastases in four of 210 patients (1.9%) with negative 68Ga-PSMA-11 PET/CT results. CONCLUSION. On a per-patient basis, the diagnostic performance of 68Ga-PSMA-11 PET/CT is superior to that of 99mTc-MDP BS for the detection of PCa bone metastases. Furthermore, 99mTc-MDP BS offers limited additional information in patients with negative 68Ga-PSMA-11 PET/CT results. CLINICAL IMPACT. According to current evidence, 99mTc-MDP BS is highly unlikely to be additive to 68Ga-PSMA-11 PET/CT in identifying bone metastases in patients with PCa.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Zhao, Ji. Head-To-Head Comparison of 68Ga-PSMA-11 PET/CT and 99mTc-MDP Bone Scintigraphy for the Detection of Bone Metastases in Patients With Prostate Cancer: A Meta-Analysis. AJR Am J Roentgenol. 2022. PMID: 35441529. doi:10.2214/AJR.21.27323

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。